Polysubstance Use Is Rewriting the Rules of Addiction Medicine

• By: Dr. Ryan Cole, PsyD Achieve Whole Recovery
• August 14th, 2026
• addiction medicine, Contingency Management, fentanyl, medetomidine, opioid use disorder, polysubstance use, stimulant use disorder, xylazine
• 343    0

Key Takeaways: Fentanyl increasingly contains sedative adulterants like xylazine and medetomidine, plus stimulants, which is complicating standard opioid use disorder treatment protocols. Xylazine's own withdrawal syndrome and its masking of opioid withdrawal signs are pushing providers...

Veterans Heroic Battle with the Opioid Epidemic

• By: Rachel W. Bush, PhD New York Medical College
• April 16th, 2020
• addiction medicine, chronic pain, Medication Assisted Treatment (MAT), mental health, naloxone, opioid misuse, trauma, veterans
• 1715    0

How can we ever fully thank our veterans for their service? As a group of health care professionals, we have an obligation to provide outstanding clinical care to this heroic population. Every Veterans Day we celebrate the service of all U.S. Military Veterans. We know that this courageous group...

Increasing the Addiction Workforce: Fellowship Training in Addiction Medicine

• By: Abigail J. Herron, DO, FAPA, FASAM The Institute for Family Health
• April 1st, 2016
• addiction medicine, behavioral health, healthcare access, integrated care, physician training, recovery, substance use disorders, training, treatment gap, workforce
• 1924    0

Substance use is one of the most significant public health issues in the United States. Annual costs related to crime, lost work productivity and health care due to use of tobacco, alcohol, and illicit drugs exceeds $700 million annually (http://www.drugabuse.gov/related-topics/trends-statistics)....